Growth hormone
Sermorelin
GHRH(1-29), formerly Geref
Sermorelin is the first 29 amino acids of growth hormone-releasing hormone and was once FDA-approved as Geref for children with growth hormone deficiency. The brand was discontinued for business reasons, and today it is mainly prepared by compounding pharmacies.
Key facts
- Commonly discussed for: supporting natural growth hormone levels in adults.
- Evidence (C): Its approval rested on pediatric growth studies, such as a 110-child Geref study where height velocity roughly doubled over 6 months. Evidence for the adult wellness uses it is discussed for today is small and largely uncontrolled.
- FDA status: Compoundable. FDA withdrew the Geref approvals in June 2009 at the maker's request and determined in March 2013 that they were not withdrawn for safety or effectiveness reasons, which compounders cite as the basis for 503A compounding.
- Legitimate access: Rx compounded (503A).
- Last reviewed: October 1, 2026.
Thinking about Sermorelin?
Add it to your stack, then bring the list to a licensed provider. They can tell you whether it fits your health picture and what the legitimate options are. Peptiblox never sells peptides or links to sellers. Check the legal status tracker for the latest FDA changes.
Open my stack →Sources
- Federal Register: Determination that GEREF (sermorelin acetate) was not withdrawn for reasons of safety or effectiveness (March 4, 2013)
- Geref International Study Group. Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient children. J Clin Endocrinol Metab, 1996
- New Drug Loft: Compounding to ensure patient access to sermorelin (2026)